APOA1 and Parkinson disease: With regard to using biomarkers for tracking the progress of PD, Yuki et al. performed protein profiling of plasma-derived exosomes from PD patients at Hoehn and Yahr (HY) stages II and III, and found that in HY stage III PD patients apolipoprotein A1 expression was significantly lower than in HY stage II PD patients.